These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38858300)

  • 21. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
    Home PD; Aroda VR; Blonde L; Guyot P; Shaunik A; Fazeli MS; Goswami H; Kalra S; Pourrahmat MM
    Diabetes Obes Metab; 2020 Nov; 22(11):2170-2178. PubMed ID: 32627297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
    Billings LK; Doshi A; Gouet D; Oviedo A; Rodbard HW; Tentolouris N; Grøn R; Halladin N; Jodar E
    Diabetes Care; 2018 May; 41(5):1009-1016. PubMed ID: 29483185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
    Blumer I; Pettus JH; Santos Cavaiola T
    Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
    Gough SC; Bode B; Woo V; Rodbard HW; Linjawi S; Poulsen P; Damgaard LH; Buse JB;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):885-93. PubMed ID: 25190523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
    Rodbard HW; Buse JB; Woo V; Vilsbøll T; Langbakke IH; Kvist K; Gough SC
    Diabetes Obes Metab; 2016 Jan; 18(1):40-8. PubMed ID: 26343931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
    Lingvay I; Handelsman Y; Linjawi S; Vilsbøll T; Halladin N; Ranc K; Liebl A
    Endocr Pract; 2019 Feb; 25(2):144-155. PubMed ID: 30383495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus.
    Novodvorský P; Haluzík M
    Expert Opin Drug Saf; 2022 Mar; 21(3):349-361. PubMed ID: 34641742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
    Castellana M; Cignarelli A; Brescia F; Laviola L; Giorgino F
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3082. PubMed ID: 30270567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Opin Drug Saf; 2017 Mar; 16(3):387-396. PubMed ID: 28150516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
    Watada H; Kaneko S; Komatsu M; Agner BR; Nishida T; Ranthe M; Nakamura J
    Diabetes Obes Metab; 2019 Dec; 21(12):2694-2703. PubMed ID: 31423685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
    Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
    J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.
    Harris S; Abrahamson MJ; Ceriello A; Charpentier G; Evans M; Lehmann R; Liebl A; Linjawi S; Holt RIG; Hosszúfalusi N; Rutten G; Vilsbøll T
    Drugs; 2020 Feb; 80(2):147-165. PubMed ID: 31960258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
    Vilsbøll T; Vora J; Jarlov H; Kvist K; Blonde L
    Clin Drug Investig; 2016 Apr; 36(4):293-303. PubMed ID: 26894800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
    Ericsson Å; Lundqvist A
    Appl Health Econ Health Policy; 2017 Apr; 15(2):237-248. PubMed ID: 28063135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.
    Davies MJ; Glah D; Chubb B; Konidaris G; McEwan P
    Pharmacoeconomics; 2016 Sep; 34(9):953-66. PubMed ID: 27438706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.
    Kumar A
    Expert Opin Biol Ther; 2014 Jun; 14(6):869-78. PubMed ID: 24702171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
    Wilding JP; Bain SC
    Diabet Med; 2016 Jul; 33(7):864-76. PubMed ID: 26525806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
    Lingvay I; Harris S; Jaeckel E; Chandarana K; Ranthe MF; Jódar E
    Diabetes Obes Metab; 2018 Jan; 20(1):200-205. PubMed ID: 28643425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.